Related references
Note: Only part of the references are listed.Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
Diana M. Negoescu et al.
INFLAMMATORY BOWEL DISEASES (2020)
Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study
Alain Attar et al.
DIGESTIVE AND LIVER DISEASE (2019)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring
Amit Assa et al.
GASTROENTEROLOGY (2019)
Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease
David R. Mack et al.
GASTROENTEROLOGY (2019)
Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study
Mallory Chavannes et al.
JOURNAL OF CROHNS & COLITIS (2019)
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naive and Non-naive Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease
Fabio Salvatore Macaluso et al.
JOURNAL OF CROHNS & COLITIS (2019)
A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease
Laurie B. Grossberg et al.
INFLAMMATORY BOWEL DISEASES (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling
Karoline Freeman et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease
Victoria Grossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score
Elena Cerrillo et al.
INFLAMMATORY BOWEL DISEASES (2015)
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
F. M. Ruemmele et al.
JOURNAL OF CROHNS & COLITIS (2014)
Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses
Monia Marchetti et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2014)
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Fernando S. Velayos et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Recent Trends in the Prevalence of Crohn's Disease and Ulcerative Colitis in a Commercially Insured US Population
Michael D. Kappelman et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Incidence, Clinical Characteristics, and Natural History of Pediatric IBD in Wisconsin: a Population-based Epidemiological Study
Tonya Adamiak et al.
INFLAMMATORY BOWEL DISEASES (2013)
Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
Amit Assa et al.
JOURNAL OF CROHNS & COLITIS (2013)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children
Jeffrey S. Hyams et al.
GASTROENTEROLOGY (2012)
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents
Pauliina Molander et al.
INFLAMMATORY BOWEL DISEASES (2012)
Incidence, Prevalence, and Time Trends of Pediatric Inflammatory Bowel Disease in Northern California, 1996 to 2006
Oren Abramson et al.
JOURNAL OF PEDIATRICS (2010)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Share Paper
